US Food and Drug Administration approves new treatment for refractory multiple myeloma (RRMM)

US Food and Drug Administration approves new treatment for refractory multiple myeloma (RRMM)

Silver Spring, MD (STL.News) – Wednesday, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

“While there is no cure for multiple myeloma, there are FDA-approved treatments to target the cancer and slow down the spread of the disease. 

Continue reading US Food and Drug Administration approves new treatment for refractory multiple myeloma (RRMM) at STL.News.